AlphaVax is assuming direct control of a vaccine manufacturing facility in Lenoir NC that it leases from Greer.

Under a new lease, AlphaVax said it would oversee operations and employment of “several” Greer staff who make AlphaVax vaccines. The companies have worked together since 200.

“Assumption of direct responsibility for our own vaccine manufacturing operations is a logical step in AlphaVax’s strategic plan,” said Andrew Graham, vice president of development at
AlphaVax. “The manufacturing process is a critical, rate-limiting step in the development of a new, complex biological technology like ours. Unlocking the potential of our core technology so that it can successfully support a broad array of new vaccine products depends on how effectively a company solves the challenges of manufacturing within the strict demands of FDA regulation. This is a long-
standing strategic priority for AlphaVax, and one where we have established strong proprietary expertise.”

AlphaVax is also renovating another leased facility for manufacturing in Durham. Graham said the additional capacity was needed to meet growing customer demand.

The company has been awarded more than $30 million in federal grants for vaccine programs related to HIV, SARS, influenza and biodefense.